Logan Capital Management Inc. Sells 8,188 Shares of Novo Nordisk A/S (NYSE:NVO)

Logan Capital Management Inc. lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 27.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,225 shares of the company's stock after selling 8,188 shares during the quarter. Logan Capital Management Inc.'s holdings in Novo Nordisk A/S were worth $1,826,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in NVO. LRI Investments LLC grew its holdings in shares of Novo Nordisk A/S by 1.4% in the 4th quarter. LRI Investments LLC now owns 13,060 shares of the company's stock valued at $1,123,000 after acquiring an additional 176 shares in the last quarter. Lighthouse Investment Partners LLC grew its stake in Novo Nordisk A/S by 148.4% in the fourth quarter. Lighthouse Investment Partners LLC now owns 38,500 shares of the company's stock valued at $3,312,000 after purchasing an additional 23,000 shares in the last quarter. JARISLOWSKY FRASER Ltd increased its position in shares of Novo Nordisk A/S by 5.4% during the 4th quarter. JARISLOWSKY FRASER Ltd now owns 77,441 shares of the company's stock worth $6,661,000 after purchasing an additional 3,944 shares during the last quarter. Guardian Wealth Advisors LLC NC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $207,000. Finally, Geller Advisors LLC raised its stake in shares of Novo Nordisk A/S by 19.1% during the 4th quarter. Geller Advisors LLC now owns 14,678 shares of the company's stock worth $1,263,000 after purchasing an additional 2,353 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NVO traded up $1.66 on Thursday, reaching $66.07. The company had a trading volume of 9,052,066 shares, compared to its average volume of 6,487,417. The stock has a market cap of $296.49 billion, a P/E ratio of 20.08, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The company's fifty day moving average is $67.84 and its 200 day moving average is $85.23.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Finally, Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.